• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.82% Nasdaq Up0.70%

    Innovus Pharmaceuticals, Inc. (INNV)

    -Other OTC
    0.27 Up 0.01(3.23%) May 25, 3:59PM EDT
    ProfileGet Profile for:
    Innovus Pharmaceuticals, Inc.
    9171 Towne Centre Drive
    Suite 440
    San Diego, CA 92122
    United States - Map
    Phone: 858-964-5123
    Fax: 858-249-7879
    Website: http://www.innovuspharma.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drug Manufacturers - Major
    Full Time Employees:1

    Business Summary 

    Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The company’s pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was incorporated in 2011 and is based in San Diego, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Innovus Pharmaceuticals, Inc.

    Key Executives 
     PayExercised
    Dr. Bassam B. Damaj Ph.D., 48
    Chief Exec. Officer, Pres, Chief Financial Officer, Chief Accounting Officer and Director
    106.00K0.00
    Mr. Randy J. Berholtz Esq., J.D., MBA, 54
    Exec. VP, Compliance Officer, Gen. Counsel and Sec.
    N/AN/A
    Mr. Robert C. Verfurth ,
    VP of Sales and Marketing
    N/AN/A
    Mr. Reuven Rubinson CPA, MBA ,
    VP of Fin.
    N/AN/A
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders